共 50 条
- [41] Real-world second-line treatment patterns and associated clinical outcomes for 2795 patients with advanced HR+HER2-breast cancer treated with first-line CDK4/6 inhibitorsCANCER RESEARCH, 2023, 83 (05)Clifton, Katherine K.Wander, Seth A.Ma, CynthiaDavis, Andrew A.Weipert, CarolineZhang, NicoleBucheit, Leslie
- [42] Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancerDRUGS OF THE FUTURE, 2022, 47 (12) : 867 - 886Wang, JingruDong, XiaotongAshby, Charles R.Chen, Zhe-ShengZhang, Yunxiang
- [44] Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)CLINICAL CANCER RESEARCH, 2021, 27 (15) : 4177 - 4185Bardia, AdityaHurvitz, Sara A.DeMichele, AngelaClark, Amy S.Zelnak, AmeliaYardley, Denise A.Karuturi, MeghanSanft, TaraBlau, SibelHart, LowellMa, CynthiaRugo, Hope S.Purkayastha, DasMoulder, Stacy
- [45] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in PanamaCANCER RESEARCH, 2023, 83 (05)Castillo-Fernandez, Omar O.Lim, MariaMontano, Lilian
- [46] Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2-metastatic breast cancer patientFRONTIERS IN ONCOLOGY, 2022, 12Pan, BoHao, ZhixinXu, YingWang, ZheYao, RuWang, XuefeiRen, ChaoZhou, YidongSun, QiangHuo, Li
- [47] Are We Prepared for the CDK4/6 Revolution With HR+/HER2- Breast Cancers?: The Importance of Patient Adherence to Adjuvant TherapiesBREAST CANCER-BASIC AND CLINICAL RESEARCH, 2023, 17Azoz, SeylaPeters, MartinJones, Graham
- [48] A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2-advanced breast cancerCANCER RESEARCH, 2023, 83 (05)Sanchez-Bayona, RodrigoAlva, Manuelde Sa, Alfonso LopezGilarranz, Yolanda Jerezde Torre, Ana SanchezTolosa, Pablode Luna, AliciaLopez-Tarruella, SaraLema, LauraMoreno, FernandoEchavarria, IsabelMadariaga, AinhoaBenitez, JavierHerrero, BlancaRey, MacarenaOrtega, JustoGamez, SalvadorModrego, AndreaLozano, Rocio MartinFiguero-Perez, LuisJimenez, RobertoSevilla, Marta GonzalezGonzalez, IreneBeranek, Marianela Bringasde Toro, MariaMassarrah, Tatianadel Monte-Millan, MariaPinardo, MarinaManso, LuisBueno-Muino, CoraliaGarcia-Saenz, Jose AngelMartin, MiguelCiruelos, Eva
- [49] Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2-breast cancer in MexicoCLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (01) : 239 - 244Molina-Jaimes, MarianaGalindo-Gonzalez, AntonioVerduzco-Aguirre, Haydee CristinaBautista-Arredondo, SergioReyes-Teran, GustavoSoto-Perez-de-Celis, Enrique
- [50] Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2− breast cancer in MexicoClinical and Translational Oncology, 2024, 26 : 239 - 244Mariana Molina-JaimesAntonio Galindo-GonzálezHaydeé Cristina Verduzco-AguirreSergio Bautista-ArredondoGustavo Reyes-TeránEnrique Soto-Perez-de-Celis